Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ocugen
< Previous
1
2
3
Next >
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
August 08, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
August 05, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
August 02, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
July 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
July 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
July 29, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
July 25, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
June 21, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
June 20, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
May 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at BIO International Convention 2024
May 29, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
May 28, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
May 15, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with First Quarter 2024 Financial Results
May 14, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
May 10, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at May 2024 Investor Conferences
May 10, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
May 03, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
May 02, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
April 29, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
April 05, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
April 02, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.